Tu1826 IMPACT OF GLP-1 RECEPTOR AGONIST ON CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS: INSIGHTS FROM A LARGE-SCALE ...

Mo1565 BASOLATERAL AMYGDALA 5-HT6 RECEPTOR: A NOVEL TARGET PRODUCES ANXIOLYTIC BEHAVIORS IN A RAT MODEL OF CCL4-INDUCED LIVER INJURY (BEHAVIORAL, ...

850 PATIENTS WITH MAFLD TAKING GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT HAVE HIGHER INCIDENCE FOR HEPATOBILIARY CANCER BUT HAVE LOWER OVERALL ...

Mo1550 SINGLE CELL RNASEQ ANALYSIS OF FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) EXPRESSION IN FIBROTIC LIVER PATHOLOGY

Su1558 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS REDUCE HEPATIC FAT CONTEXT INDEPENDENT OF THE WEIGHT LOSS IN DIABETIC PATIENTS WITH METABOLIC ...

39 SINGLE-CELL RNA PROFILING AND HIGH-THROUGHPUT SCREENING DISCOVERED MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA AND HISTAMINE 1 RECEPTOR AS KEY PATHWAYS IN C. ...

Sa1451 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USE DOES NOT INCREASE THE RISK FOR ACUTE PANCREATITIS AND IS ASSOCIATED WITH LOWER COMPLICATIONS IN ...

Sa1959 NO INCREASED RISK OF DE-NOVO ACUTE PANCREATITIS IN NONDIABETIC WITH OBESITY PATIENTS ON GLP-1 RECEPTOR AGONISTS FOR WEIGHT LOSS: A MULTI-NETWORK ...

15 EXPLORING THE ANTINOCICEPTIVE EFFECT OF INDOLES AND THE ARYL HYDROCARBON RECEPTOR IN AN EXPERIMENTAL MODEL OF IBD IN REMISSION

Hepatocellular carcinoma (HCC) is a leading cause of cancer death. HCC is preventable with about 70 percent of HCC attributable to modifiable risk factors. ...